Integra LifeSciences Holdings Corp (Integra) is a medical technology company, focused on harnessing its engineered collagen-based technology in its varied product lines, which are used in various applications ranging from burns and deep tissue wounds to the repair of nerve and tendon and to repair of dura mater in the brain. The company’s products serve neurosurgery, orthopedic extremity surgery, reconstructive and general surgery, and spine surgery, among others. It directly sales its products in more than 120 countries to the distributors and wholesalers.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Integra focuses on introducing new products to strengthen and expand its portfolio through clinical evidence to support regulatory approval and strong reimbursement globally. The company's research and development activities aim to identify unmet surgical needs and address them with innovative solutions and products. Investment in research and development is critical for driving future growth, focusing on the further development and improvement of existing products, the design and development of new innovative medical technologies, and regulatory compliance across all business segments. The company applies its core competency in regenerative technology to innovate products for neurosurgical, wound applications, plastic surgery, and reconstructive surgery, with extensive R&D programs for core platforms of electromechanical technologies. Additionally, Integra LifeSciences conducts projects and clinical studies to generate efficacy and health economic evidence. The Company’s R&D units include Neurosurgical Solutions, Surgical Instruments, and ENT Solutions. These units are responsible for managing the company's R&D activities, focusing on life cycle management and innovation for capital and disposable products in the portfolio. The product development efforts are centered on core clinical applications in cerebrospinal fluid management, neuro-critical care monitoring, minimally invasive instruments, electrosurgery, and ultrasonic medical technologies. The company aims to transform the standard of care in neurosurgery with product advancements in minimally invasive surgery and the surgical management of intracerebral hemorrhage. In FY2025, the company spent US$80.77 million on its R&D activities, which as a percentage of revenue stood at 11.3%. The company operates research facilities in California, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, and Utah in the US; and Canada, China, France, Germany, Ireland and Switzerland.